Purdue slashes work force as generic OxyContin gets green light

With a generic version of OxyContin on the way, Purdue Pharma says it will be forced to lay off more than 800 workers, or 38 percent of its employees. OxyContin accounts for 75 percent of the company's revenues. Among those affected are 290 employees at the company's headquarters in Stamford, Connecticut. The company has other painkillers in the pipeline and is also developing a generic version of OxyContin.

- read this report from the San Diego Union-Tribune for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.